Sukhi Jagpal Net Worth

Sukhi Jagpal biography

Sukhi Jagpal serves as Chief Financial Officer of the Company. Previously, Mr. Jagpal served as the Chief Financial Officer of QLT Inc., a biotechnology company, from July 2012 to February 2015, where he also served as the Senior Director, Finance and Corporate Controller from January 2011 to June 2012. Mr. Jagpal has also held senior finance positions with Pivotal Corporation, 360networks Inc. and KPMG LLP. Mr. Jagpal is a Chartered Professional Accountant, a Chartered Business Valuator and holds an M.B.A. from Cornell University – S.C. Johnson Graduate School of Management and an M.B.A. from Queens University.

What is the salary of Sukhi Jagpal?

As the Chief Financial Officer of Sierra Oncology Inc, the total compensation of Sukhi Jagpal at Sierra Oncology Inc is $859,428. There are 2 executives at Sierra Oncology Inc getting paid more, with Barbara Klencke having the highest compensation of $971,397.

How old is Sukhi Jagpal?

Sukhi Jagpal is 46, he's been the Chief Financial Officer of Sierra Oncology Inc since 2015. There are 16 older and 1 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.

What's Sukhi Jagpal's mailing address?

Sukhi's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Sierra Oncology Inc

Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth, and James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.

What does Sierra Oncology Inc do?

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

Sierra Oncology Inc executives and stock owners

Sierra Oncology Inc executives and other stock owners filed with the SEC include:

• Barbara Klencke,
  Chief Development Officer
• Mark Kowalski,
  Chief Medical Officer
• Sukhi Jagpal,
  Chief Financial Officer
• Dr. Stephen George Dilly M.B.B.S, Ph.D.,
  Pres, CEO & Director
• Dr. Barbara J. Klencke M.D.,
  Chief Medical Officer
• Dr. Mark M. Kowalski M.D., Ph.D.,
  Chief of Research & Early Devel.
• Robert Pelzer,
  Independent Chairman of the Board
• James Smith,
  Vice President Corporate Affairs
• Andrew Sinclair,
  Independent Director
• Josh Richardson,
  Independent Director
• Jeffrey Cooper,
  Independent Director
• Mona Ashiya,
  Independent Director
• Andrew Allen,
  Independent Director
• Gaurav Aggarwal,
  Independent Director
• Craig Collard,
  Director
• William Turner,
  Chief Regulatory and Technical Operations Officer
• Kevin Norrett,
  Chief Business Officer
• Christina Thomson,
  General Counsel
• Stephen Dilly,
  President, Chief Executive Officer, Director
• Kevin Norrett M.B.A., M.S.,
  Chief Bus. Officer
• William D. Turner,
  Chief Regulatory & Technical Operations Officer
• Christina Thomson J.D., M.S.,
  Gen. Counsel, Chief Compliance Officer & Sec.
• Sukhi Jagpal CA, CPA, CBV, MBA,
  Chief Financial Officer
• Daniel Estes,
  Director
• James N Topper,
  Director
• Nicholas Glover,
  CEO and President
• Nicole Onetto,
  Director
• Tran Nguyen,
  Director
• Donald R Parfet,
  Director
• Angie You,
  Chief Bus. & Strat. Officer
• Capital Partners Iii, Llc L...,
  
• Christian Hassig,
  Chief Scientific Officer
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llcorbimed Capital...,
  
• Opportunity, Llc Vivo Oppor...,
  
• Advisors Llc Orbi Med Capit...,
  
• Georgia Erbez,
  Director
• Christy J. Oliger,
  Director
• Llp Abingworth,
  10% owner
• Mary Christina Thomson,
  General Counsel
• Advisors Llc Orbi Med Capit...,